CUE BIOPHARMA INC (CUE) Stock Price, Quote, News and Overview
NASDAQ:CUE - Nasdaq - US22978P1066 - Common Stock - Currency: USD
CUE Quote, Performance and Key Statistics
NASDAQ:CUE (2/21/2025, 8:11:19 PM)
1.32
-0.05 (-3.65%)
The current stock price of CUE is 1.32 USD. In the past month the price decreased by -5.04%. In the past year, price decreased by -34.33%.
CUE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CUE
Company Profile
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. The company is headquartered in Boston, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2018-01-02. The firm's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
Company Info
CUE BIOPHARMA INC
40 Guest Street
Boston MASSACHUSETTS 02139 US
CEO: Daniel R. Passeri
Employees: 53
Company Website: https://www.cuebiopharma.com/
Investor Relations: https://www.cuebiopharma.com/investors-media/
Phone: 16179492680
CUE BIOPHARMA INC / CUE FAQ
What is the stock price of CUE BIOPHARMA INC today?
The current stock price of CUE is 1.32 USD. The price decreased by -3.65% in the last trading session.
What is the ticker symbol for CUE BIOPHARMA INC stock?
The exchange symbol of CUE BIOPHARMA INC is CUE and it is listed on the Nasdaq exchange.
On which exchange is CUE stock listed?
CUE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CUE BIOPHARMA INC stock?
9 analysts have analysed CUE and the average price target is 3.67 USD. This implies a price increase of 178.18% is expected in the next year compared to the current price of 1.32. Check the CUE BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CUE BIOPHARMA INC worth?
CUE BIOPHARMA INC (CUE) has a market capitalization of 83.62M USD. This makes CUE a Micro Cap stock.
How many employees does CUE BIOPHARMA INC have?
CUE BIOPHARMA INC (CUE) currently has 53 employees.
What are the support and resistance levels for CUE BIOPHARMA INC (CUE) stock?
CUE BIOPHARMA INC (CUE) has a support level at 1.31 and a resistance level at 1.33. Check the full technical report for a detailed analysis of CUE support and resistance levels.
Is CUE BIOPHARMA INC (CUE) expected to grow?
The Revenue of CUE BIOPHARMA INC (CUE) is expected to grow by 94.59% in the next year. Check the estimates tab for more information on the CUE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CUE BIOPHARMA INC (CUE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CUE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CUE, evaluating the profitability, health, valuation and growth aspects
- CUE BIOPHARMA INC (CUE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CUE BIOPHARMA INC (CUE) Sales and EPS estimates to see what analysts future expectations are.
- CUE BIOPHARMA INC (CUE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CUE BIOPHARMA INC (CUE) Insider and Institutional Ownership to learn about the owners and their transactions.
- CUE BIOPHARMA INC (CUE) Stock Chart to make your own analysis
- CUE BIOPHARMA INC (CUE) Latest news and press-releases to stay up to date.
Does CUE BIOPHARMA INC (CUE) stock pay dividends?
CUE does not pay a dividend.
When does CUE BIOPHARMA INC (CUE) report earnings?
CUE BIOPHARMA INC (CUE) will report earnings on 2025-03-12, after the market close.
What is the Price/Earnings (PE) ratio of CUE BIOPHARMA INC (CUE)?
CUE BIOPHARMA INC (CUE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.91).
What is the Short Interest ratio of CUE BIOPHARMA INC (CUE) stock?
The outstanding short interest for CUE BIOPHARMA INC (CUE) is 1.74% of its float. Check the ownership tab for more information on the CUE short interest.
CUE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CUE. When comparing the yearly performance of all stocks, CUE is a bad performer in the overall market: 65.88% of all stocks are doing better.
CUE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CUE. CUE may be in some trouble as it scores bad on both profitability and health.
CUE Financial Highlights
Over the last trailing twelve months CUE reported a non-GAAP Earnings per Share(EPS) of -0.91. The EPS increased by 24.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -99.56% | ||
| ROE | -175.87% | ||
| Debt/Equity | 0.05 |
CUE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to CUE. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 30.66% and a revenue growth 94.59% for CUE